 Eva Nozik
Concepts (380)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Superoxide Dismutase | 22 | 2025 | 342 | 6.410 |
Why?
| | Hypertension, Pulmonary | 25 | 2025 | 1894 | 2.800 |
Why?
| | Acute Lung Injury | 8 | 2023 | 280 | 2.580 |
Why?
| | Hypoxia | 10 | 2025 | 1084 | 2.280 |
Why?
| | Pneumonia, Staphylococcal | 2 | 2025 | 21 | 1.750 |
Why?
| | Lung | 29 | 2025 | 3938 | 1.670 |
Why?
| | Vascular Remodeling | 7 | 2025 | 192 | 1.560 |
Why?
| | Blood Platelets | 4 | 2025 | 382 | 1.530 |
Why?
| | Mice, Inbred C57BL | 21 | 2025 | 5455 | 1.500 |
Why?
| | Hyaluronic Acid | 3 | 2025 | 216 | 1.490 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2024 | 2060 | 1.270 |
Why?
| | Bleomycin | 8 | 2018 | 243 | 1.250 |
Why?
| | Platelet Activation | 4 | 2025 | 91 | 1.180 |
Why?
| | Pneumonia | 5 | 2022 | 617 | 1.100 |
Why?
| | Pulmonary Artery | 13 | 2021 | 1097 | 1.090 |
Why?
| | Hypertrophy, Right Ventricular | 8 | 2022 | 145 | 1.010 |
Why?
| | Mice | 38 | 2025 | 16961 | 1.000 |
Why?
| | Animals | 61 | 2025 | 35391 | 0.970 |
Why?
| | Oxidation-Reduction | 6 | 2023 | 1028 | 0.940 |
Why?
| | Lung Injury | 5 | 2021 | 211 | 0.910 |
Why?
| | Reactive Oxygen Species | 9 | 2025 | 593 | 0.900 |
Why?
| | Macrophages, Alveolar | 6 | 2024 | 389 | 0.890 |
Why?
| | Myocytes, Smooth Muscle | 7 | 2025 | 259 | 0.890 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2022 | 379 | 0.880 |
Why?
| | Superoxides | 2 | 2025 | 201 | 0.850 |
Why?
| | Cell Communication | 1 | 2025 | 301 | 0.840 |
Why?
| | Macrophages | 5 | 2025 | 1488 | 0.820 |
Why?
| | Inflammation | 10 | 2025 | 2750 | 0.800 |
Why?
| | Disease Models, Animal | 13 | 2025 | 4078 | 0.790 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2017 | 28 | 0.700 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 220 | 0.660 |
Why?
| | Neutrophils | 1 | 2025 | 1210 | 0.640 |
Why?
| | Endothelium, Vascular | 4 | 2018 | 903 | 0.640 |
Why?
| | Receptor, EphA2 | 2 | 2018 | 19 | 0.640 |
Why?
| | Pulmonary Fibrosis | 4 | 2017 | 385 | 0.630 |
Why?
| | Alpha-Globulins | 2 | 2018 | 20 | 0.610 |
Why?
| | Mice, Knockout | 9 | 2025 | 2881 | 0.590 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 20 | 0.570 |
Why?
| | Protective Agents | 1 | 2018 | 39 | 0.570 |
Why?
| | Liposomes | 3 | 2017 | 171 | 0.560 |
Why?
| | Endothelial Cells | 4 | 2015 | 749 | 0.540 |
Why?
| | Staphylococcus aureus | 3 | 2025 | 434 | 0.500 |
Why?
| | MicroRNAs | 2 | 2022 | 679 | 0.500 |
Why?
| | Early Growth Response Protein 1 | 2 | 2011 | 28 | 0.460 |
Why?
| | Vasodilator Agents | 6 | 2017 | 326 | 0.450 |
Why?
| | Pulmonary Alveoli | 2 | 2021 | 403 | 0.430 |
Why?
| | Signal Transduction | 7 | 2024 | 4931 | 0.420 |
Why?
| | Mice, Transgenic | 7 | 2025 | 2128 | 0.420 |
Why?
| | Extracellular Space | 2 | 2011 | 120 | 0.420 |
Why?
| | Peptides | 2 | 2018 | 926 | 0.420 |
Why?
| | Oxidative Stress | 7 | 2025 | 1266 | 0.400 |
Why?
| | Mitochondria | 1 | 2019 | 876 | 0.400 |
Why?
| | Metalloporphyrins | 1 | 2013 | 101 | 0.390 |
Why?
| | Hemoglobins | 4 | 2017 | 339 | 0.390 |
Why?
| | Xanthine Oxidase | 1 | 2011 | 78 | 0.370 |
Why?
| | Inflammasomes | 1 | 2013 | 126 | 0.370 |
Why?
| | Animals, Newborn | 5 | 2022 | 835 | 0.360 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 169 | 0.350 |
Why?
| | Extracellular Matrix | 2 | 2025 | 506 | 0.350 |
Why?
| | Lipopolysaccharides | 4 | 2023 | 877 | 0.350 |
Why?
| | Cell Proliferation | 8 | 2022 | 2373 | 0.340 |
Why?
| | Male | 28 | 2025 | 63670 | 0.340 |
Why?
| | Up-Regulation | 2 | 2013 | 840 | 0.320 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2025 | 444 | 0.320 |
Why?
| | Trachea | 1 | 2010 | 226 | 0.310 |
Why?
| | Carrier Proteins | 1 | 2013 | 745 | 0.300 |
Why?
| | Sildenafil Citrate | 2 | 2018 | 59 | 0.280 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 651 | 0.280 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2018 | 123 | 0.280 |
Why?
| | Energy Metabolism | 2 | 2024 | 875 | 0.280 |
Why?
| | Rats, Sprague-Dawley | 10 | 2018 | 2395 | 0.260 |
Why?
| | Electron Spin Resonance Spectroscopy | 2 | 2023 | 91 | 0.260 |
Why?
| | Kidney | 3 | 2024 | 1386 | 0.260 |
Why?
| | Nanoparticles | 2 | 2021 | 375 | 0.250 |
Why?
| | Cells, Cultured | 6 | 2021 | 4084 | 0.240 |
Why?
| | Humans | 36 | 2024 | 129625 | 0.240 |
Why?
| | Acute Kidney Injury | 2 | 2024 | 791 | 0.240 |
Why?
| | Rats | 11 | 2018 | 5483 | 0.240 |
Why?
| | Platelet Factor 4 | 2 | 2025 | 34 | 0.230 |
Why?
| | Neutrophil Infiltration | 1 | 2025 | 105 | 0.230 |
Why?
| | Serotonin | 2 | 2024 | 318 | 0.230 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 2024 | 26 | 0.230 |
Why?
| | Gene Expression Regulation | 5 | 2018 | 2542 | 0.230 |
Why?
| | Myofibroblasts | 3 | 2022 | 122 | 0.230 |
Why?
| | Prolactin | 1 | 2024 | 97 | 0.220 |
Why?
| | Cellular Reprogramming | 1 | 2024 | 95 | 0.220 |
Why?
| | Hydroxylamine | 1 | 2023 | 7 | 0.220 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 183 | 0.210 |
Why?
| | Interleukin-1beta | 2 | 2018 | 372 | 0.210 |
Why?
| | Influenza A virus | 1 | 2024 | 100 | 0.210 |
Why?
| | Fibroblast Growth Factors | 1 | 2024 | 169 | 0.210 |
Why?
| | Nitric Oxide | 4 | 2018 | 895 | 0.210 |
Why?
| | NF-kappa B | 3 | 2018 | 665 | 0.210 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2018 | 199 | 0.200 |
Why?
| | Liver | 2 | 2024 | 1842 | 0.200 |
Why?
| | Coinfection | 1 | 2024 | 131 | 0.200 |
Why?
| | Uncoupling Protein 2 | 1 | 2022 | 8 | 0.200 |
Why?
| | Hyaluronan Synthases | 1 | 2022 | 1 | 0.200 |
Why?
| | Wound Healing | 1 | 2025 | 307 | 0.200 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2023 | 58 | 0.200 |
Why?
| | Glutathione | 1 | 2024 | 348 | 0.200 |
Why?
| | Interleukin-10 | 1 | 2024 | 300 | 0.190 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2015 | 203 | 0.190 |
Why?
| | Adventitia | 2 | 2012 | 43 | 0.180 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2021 | 11 | 0.180 |
Why?
| | Succinate Dehydrogenase | 1 | 2021 | 45 | 0.180 |
Why?
| | Alveolar Epithelial Cells | 2 | 2023 | 107 | 0.180 |
Why?
| | Chemokine CCL5 | 1 | 2020 | 43 | 0.180 |
Why?
| | Interferon-gamma | 1 | 2024 | 772 | 0.180 |
Why?
| | Placenta | 2 | 2024 | 723 | 0.180 |
Why?
| | Cell Membrane Permeability | 2 | 2018 | 82 | 0.170 |
Why?
| | Lung Diseases | 3 | 2017 | 741 | 0.170 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 147 | 0.170 |
Why?
| | Hemodynamics | 4 | 2018 | 1090 | 0.160 |
Why?
| | Staphylococcal Infections | 1 | 2024 | 389 | 0.160 |
Why?
| | Reperfusion Injury | 1 | 2022 | 272 | 0.160 |
Why?
| | Advisory Committees | 1 | 2020 | 216 | 0.160 |
Why?
| | Ephrin-A2 | 1 | 2018 | 4 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2017 | 646 | 0.150 |
Why?
| | Chronic Disease | 2 | 2017 | 1720 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2020 | 186 | 0.150 |
Why?
| | Heparitin Sulfate | 1 | 2018 | 42 | 0.150 |
Why?
| | Glycocalyx | 1 | 2018 | 22 | 0.150 |
Why?
| | Drug Repositioning | 1 | 2018 | 26 | 0.150 |
Why?
| | Glioma | 1 | 2022 | 348 | 0.150 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.150 |
Why?
| | Mucociliary Clearance | 1 | 2018 | 42 | 0.150 |
Why?
| | Ventricular Pressure | 2 | 2015 | 45 | 0.150 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 40 | 0.140 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 31 | 0.140 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2018 | 102 | 0.140 |
Why?
| | Physical Exertion | 1 | 2018 | 205 | 0.140 |
Why?
| | Blood Pressure | 5 | 2022 | 1736 | 0.140 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 31 | 0.130 |
Why?
| | PPAR gamma | 1 | 2018 | 183 | 0.130 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2017 | 37 | 0.130 |
Why?
| | Caspase 1 | 2 | 2018 | 143 | 0.130 |
Why?
| | Arginine | 2 | 2014 | 263 | 0.130 |
Why?
| | rho-Associated Kinases | 2 | 2017 | 87 | 0.130 |
Why?
| | Heart Ventricles | 1 | 2021 | 781 | 0.130 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 574 | 0.120 |
Why?
| | Disease Progression | 3 | 2019 | 2627 | 0.120 |
Why?
| | Ventricular Function, Right | 2 | 2015 | 276 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 84 | 0.120 |
Why?
| | MAP Kinase Signaling System | 2 | 2021 | 313 | 0.120 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1250 | 0.120 |
Why?
| | Cholestasis | 1 | 2018 | 232 | 0.120 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 634 | 0.120 |
Why?
| | Administration, Inhalation | 4 | 2018 | 667 | 0.120 |
Why?
| | Anemia, Sickle Cell | 1 | 2018 | 252 | 0.120 |
Why?
| | Haptoglobins | 1 | 2015 | 52 | 0.120 |
Why?
| | Pericytes | 1 | 2014 | 28 | 0.110 |
Why?
| | Hyperoxia | 1 | 1995 | 90 | 0.110 |
Why?
| | Altitude | 1 | 2018 | 462 | 0.110 |
Why?
| | Fibroblasts | 4 | 2025 | 953 | 0.110 |
Why?
| | Female | 11 | 2025 | 68734 | 0.110 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2014 | 133 | 0.110 |
Why?
| | Vascular Diseases | 2 | 2015 | 240 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 591 | 0.100 |
Why?
| | Alprostadil | 1 | 2013 | 32 | 0.100 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 97 | 0.100 |
Why?
| | I-kappa B Kinase | 1 | 2013 | 54 | 0.100 |
Why?
| | Apoptosis | 4 | 2022 | 2492 | 0.100 |
Why?
| | Lactic Acid | 3 | 2023 | 298 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 530 | 0.100 |
Why?
| | I-kappa B Proteins | 1 | 2013 | 79 | 0.100 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2013 | 79 | 0.100 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2015 | 231 | 0.100 |
Why?
| | Transcriptome | 1 | 2018 | 876 | 0.100 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2015 | 204 | 0.100 |
Why?
| | Protein Binding | 1 | 2018 | 2124 | 0.100 |
Why?
| | Altitude Sickness | 1 | 2013 | 141 | 0.090 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2013 | 149 | 0.090 |
Why?
| | Interleukin-18 | 1 | 2013 | 237 | 0.090 |
Why?
| | Neoplasm Proteins | 1 | 2014 | 419 | 0.090 |
Why?
| | Catalase | 4 | 2015 | 128 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1687 | 0.090 |
Why?
| | Vasoconstrictor Agents | 2 | 2022 | 127 | 0.090 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2011 | 51 | 0.090 |
Why?
| | Transcriptional Activation | 1 | 2013 | 367 | 0.090 |
Why?
| | Blood Vessels | 1 | 2012 | 187 | 0.090 |
Why?
| | Drug Carriers | 3 | 2018 | 119 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2046 | 0.090 |
Why?
| | Phosphorylation | 1 | 2015 | 1713 | 0.090 |
Why?
| | Rats, Inbred WKY | 1 | 2010 | 35 | 0.090 |
Why?
| | Drug Administration Routes | 1 | 2010 | 38 | 0.090 |
Why?
| | Stress, Physiological | 2 | 2012 | 414 | 0.090 |
Why?
| | Blood Circulation | 1 | 2010 | 41 | 0.090 |
Why?
| | Nitrosation | 1 | 2010 | 8 | 0.090 |
Why?
| | Accreditation | 1 | 2011 | 80 | 0.090 |
Why?
| | Microvessels | 1 | 2011 | 82 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3080 | 0.090 |
Why?
| | Airway Remodeling | 1 | 2011 | 64 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2274 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2013 | 505 | 0.080 |
Why?
| | Models, Biological | 1 | 2017 | 1724 | 0.080 |
Why?
| | Phenotype | 2 | 2015 | 3075 | 0.080 |
Why?
| | Tyrosine | 1 | 2010 | 223 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1221 | 0.080 |
Why?
| | Workload | 1 | 2011 | 153 | 0.080 |
Why?
| | Vasoconstriction | 1 | 2010 | 199 | 0.080 |
Why?
| | Cattle | 1 | 2011 | 977 | 0.080 |
Why?
| | Fetus | 1 | 2013 | 774 | 0.070 |
Why?
| | Gene Expression | 1 | 2013 | 1465 | 0.070 |
Why?
| | Time Factors | 1 | 2018 | 6555 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2010 | 460 | 0.070 |
Why?
| | Porosity | 2 | 2018 | 92 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2022 | 274 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 887 | 0.070 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 442 | 0.070 |
Why?
| | Sheep | 2 | 2022 | 845 | 0.060 |
Why?
| | Critical Care | 1 | 2011 | 551 | 0.060 |
Why?
| | Antioxidants | 3 | 2014 | 558 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2024 | 3378 | 0.060 |
Why?
| | Polyglycolic Acid | 2 | 2017 | 39 | 0.060 |
Why?
| | Sulfonamides | 2 | 2022 | 497 | 0.060 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 24 | 0.060 |
Why?
| | Schistosoma | 1 | 2024 | 28 | 0.060 |
Why?
| | Complement C5a | 1 | 2024 | 70 | 0.060 |
Why?
| | Lipid Peroxidation | 2 | 2017 | 151 | 0.060 |
Why?
| | Complement C3a | 1 | 2024 | 41 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2010 | 1075 | 0.060 |
Why?
| | Schistosomiasis | 1 | 2024 | 47 | 0.060 |
Why?
| | Maternal Behavior | 1 | 2024 | 74 | 0.060 |
Why?
| | Cell Line | 3 | 2015 | 2784 | 0.050 |
Why?
| | Pituitary Gland | 1 | 2024 | 148 | 0.050 |
Why?
| | Orthomyxoviridae Infections | 1 | 2024 | 67 | 0.050 |
Why?
| | Vascular Resistance | 2 | 2015 | 371 | 0.050 |
Why?
| | Nitrogen Oxides | 1 | 2023 | 52 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2015 | 135 | 0.050 |
Why?
| | Phosphofructokinase-2 | 1 | 2022 | 15 | 0.050 |
Why?
| | Gene Deletion | 1 | 2024 | 382 | 0.050 |
Why?
| | Breath Tests | 1 | 2023 | 87 | 0.050 |
Why?
| | Pediatrics | 1 | 2011 | 1056 | 0.050 |
Why?
| | Spectrum Analysis | 1 | 2023 | 89 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1936 | 0.050 |
Why?
| | Creatinine | 1 | 2024 | 490 | 0.050 |
Why?
| | Lasers | 1 | 2023 | 132 | 0.050 |
Why?
| | Tryptophan Hydroxylase | 1 | 2022 | 53 | 0.050 |
Why?
| | Glycolysis | 1 | 2024 | 315 | 0.050 |
Why?
| | Biomarkers | 2 | 2024 | 3968 | 0.050 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 76 | 0.050 |
Why?
| | Hydrogen Peroxide | 2 | 2012 | 317 | 0.050 |
Why?
| | Cerium | 1 | 2021 | 14 | 0.050 |
Why?
| | 3' Untranslated Regions | 1 | 2022 | 138 | 0.050 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2022 | 116 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2024 | 318 | 0.050 |
Why?
| | Complement Activation | 1 | 2024 | 384 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 234 | 0.040 |
Why?
| | Internship and Residency | 1 | 2011 | 1050 | 0.040 |
Why?
| | Ischemia | 1 | 2024 | 406 | 0.040 |
Why?
| | Metabolome | 1 | 2024 | 340 | 0.040 |
Why?
| | Angiotensin II | 1 | 2021 | 95 | 0.040 |
Why?
| | Pregnancy | 2 | 2024 | 6417 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2022 | 239 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 217 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2024 | 5756 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 3717 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2021 | 179 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2023 | 482 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 526 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 84 | 0.040 |
Why?
| | Syndecans | 1 | 2018 | 5 | 0.040 |
Why?
| | Metabolomics | 1 | 2024 | 653 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2018 | 59 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 205 | 0.040 |
Why?
| | Caspases, Initiator | 1 | 2018 | 17 | 0.040 |
Why?
| | Amino Acid Oxidoreductases | 2 | 1995 | 19 | 0.040 |
Why?
| | Liver X Receptors | 1 | 2018 | 31 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2018 | 37 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2023 | 1843 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 62 | 0.040 |
Why?
| | Needs Assessment | 1 | 2020 | 357 | 0.040 |
Why?
| | Drug Liberation | 1 | 2018 | 30 | 0.040 |
Why?
| | Influenza, Human | 1 | 2024 | 601 | 0.040 |
Why?
| | Capillary Permeability | 1 | 2018 | 141 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 277 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 712 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1833 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 97 | 0.040 |
Why?
| | Stem Cells | 2 | 2012 | 575 | 0.030 |
Why?
| | Nitric Oxide Synthase | 2 | 1995 | 237 | 0.030 |
Why?
| | Monocrotaline | 1 | 2017 | 28 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1592 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 218 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 16 | 0.030 |
Why?
| | Lipoproteins | 1 | 2018 | 172 | 0.030 |
Why?
| | Polyethyleneimine | 1 | 2017 | 18 | 0.030 |
Why?
| | Caspases | 1 | 2018 | 245 | 0.030 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 104 | 0.030 |
Why?
| | Histones | 1 | 2022 | 589 | 0.030 |
Why?
| | Hepatocytes | 1 | 2018 | 216 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1002 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 165 | 0.030 |
Why?
| | Hemolysis | 1 | 2018 | 199 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2017 | 107 | 0.030 |
Why?
| | Microspheres | 1 | 2017 | 124 | 0.030 |
Why?
| | Rabbits | 2 | 1995 | 779 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 758 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 958 | 0.030 |
Why?
| | Models, Animal | 1 | 2018 | 378 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 217 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 118 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 875 | 0.030 |
Why?
| | Sex Factors | 1 | 2022 | 1970 | 0.030 |
Why?
| | Surface Properties | 1 | 2017 | 397 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 2021 | 0.030 |
Why?
| | Particle Size | 1 | 2017 | 351 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1042 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 1995 | 48 | 0.030 |
Why?
| | Free Radicals | 1 | 1995 | 105 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1995 | 106 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2022 | 3186 | 0.030 |
Why?
| | Sepharose | 1 | 2014 | 33 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 787 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 223 | 0.030 |
Why?
| | Platelet Activating Factor | 1 | 1994 | 75 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 158 | 0.030 |
Why?
| | Glycine | 1 | 2014 | 165 | 0.030 |
Why?
| | Infant, Premature | 1 | 2017 | 542 | 0.030 |
Why?
| | Permeability | 1 | 2013 | 157 | 0.030 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2013 | 10 | 0.030 |
Why?
| | Endothelin-1 | 1 | 2015 | 179 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2013 | 53 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2013 | 54 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 119 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2017 | 723 | 0.030 |
Why?
| | von Willebrand Factor | 1 | 2013 | 71 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 254 | 0.030 |
Why?
| | Iron | 1 | 2015 | 282 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 119 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2012 | 29 | 0.020 |
Why?
| | Drug Stability | 1 | 2013 | 159 | 0.020 |
Why?
| | Vasa Vasorum | 1 | 2012 | 37 | 0.020 |
Why?
| | Infusion Pumps | 1 | 2012 | 31 | 0.020 |
Why?
| | Spin Labels | 1 | 2012 | 46 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1101 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2013 | 146 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2013 | 172 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1491 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5426 | 0.020 |
Why?
| | Cardiac Output | 1 | 2012 | 156 | 0.020 |
Why?
| | Aerosols | 1 | 2013 | 171 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 235 | 0.020 |
Why?
| | Receptor, TIE-2 | 1 | 2011 | 12 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 264 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 778 | 0.020 |
Why?
| | Cerebellum | 1 | 2013 | 218 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 412 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2011 | 129 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4404 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7135 | 0.020 |
Why?
| | Vasculitis | 1 | 2011 | 65 | 0.020 |
Why?
| | Oxygen | 1 | 1995 | 915 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 1076 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 476 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1206 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2013 | 2708 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1035 | 0.020 |
Why?
| | Thrombosis | 1 | 2011 | 348 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1207 | 0.020 |
Why?
| | Genes | 1 | 1986 | 227 | 0.020 |
Why?
| | Infant | 1 | 2017 | 8995 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 10219 | 0.010 |
Why?
| | Aged | 1 | 2022 | 22061 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2011 | 1891 | 0.010 |
Why?
| | Child | 1 | 2022 | 20884 | 0.010 |
Why?
| | Risk Factors | 1 | 2014 | 9786 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1986 | 1418 | 0.010 |
Why?
| | Ditiocarb | 1 | 1994 | 3 | 0.010 |
Why?
| | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1994 | 12 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1994 | 11 | 0.010 |
Why?
| | United States | 1 | 2011 | 13871 | 0.010 |
Why?
| | Epoprostenol | 1 | 1994 | 136 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 197 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1994 | 1087 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1986 | 368 | 0.000 |
Why?
| | Molecular Weight | 1 | 1986 | 329 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1986 | 315 | 0.000 |
Why?
| | Aging | 1 | 1986 | 1778 | 0.000 |
Why?
|
|
Nozik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|